PROJECT RENAISSANCE (Sagent in China)
Successful Pharma M&A Advisory Services
Sagent Pharmaceuticals, Inc. retained the experts at PharmaBioSource to serve as M&A consultants and advisors to assist in the divestiture of its Chinese-owned subsidiary.
Sagent (China) Pharmaceuticals, Co. Ltd., or Project Renaissance, represented a significant and potentially lucrative investment on the part of the acquiring party.
Project Renaissance involved the marketing and sale of an injectable manufacturing and development company located in Chengdu, China. With over 180 employees in a new, $100M 170,000 SF FDA-licensed aseptic facility, Project Renaissance was able to focus on high-potency products and generic injectables aimed at the U.S. market.
To help Sagent Pharmaceuticals, Inc. achieve their goal of divesting the Chinese subsidiary, PharmaBioSource went to work reviewing the business structure and site capability to develop a value proposition and place the property in front of the right parties.
We utilized the full gamut of our M&A consulting and advisory services to make the perfect match for Project Renaissance, without shortcuts.
Services provided by the PharmaBioSource team:
Within 8 short months of the initial engagement, Project Renaissance was acquired by Nanjing King-friend with an additional multi-million dollar, multi-year supply agreement included as part of the Project Renaissance deal.